Tempest Therapeutics Q2 2025 Earnings Results & Report

Tempest Therapeutics EPS Results

• Actual EPS: -$2.07
• Consensus EPS: -$3.23
• Beat/Miss: Beat by +$1.16
• One Year Ago EPS: N/A
• EPS Beat Rate: 3 of last 8 quarters

Tempest Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Tempest Therapeutics (NASDAQ:TPST) is a clinical-stage biotechnology company focused on developing small-molecule medicines for cancer. The company’s research combines tumor-targeted immune activation with approaches designed to disrupt tumor metabolism, with the goal of stimulating the immune system within the tumor microenvironment while limiting effects on healthy tissue.

Tempest’s pipeline has included TPST-1120, an oral, selective antagonist of peroxisome proliferator-activated receptor alpha (PPARα). The company has evaluated TPST-1120 as a monotherapy and in combination with immune checkpoint inhibitors for advanced solid tumors, including hepatocellular carcinoma. Tempest has also developed additional early-stage oncology programs, including TPST-1495, an investigational small-molecule inhibitor of cyclooxygenase enzymes.

Founded in 2018 and headquartered in the United States, Tempest advances its programs through clinical studies conducted in collaboration with medical centers and research partners. Its activities are primarily focused on the development of therapies for patients with advanced cancers rather than on commercialized products. Stephen Brady has served as the company’s president and chief executive officer.